By sequencing the HGF and MET genes in patients with lymphedema and patients with secondary lymphedema after cancer treatment, Finegold DN et al. reported that four HGF mutations and two MET gene mutations were closely associated with multiple types of lymphedema, which may provide therapeutic targets for lymphedema (Finegold et al., 2008). This evidence concerns the gene MET and cancer.